Upcoming events and conferences for NXTCL
Stem cell company NextCell Pharma AB ("NXTCL") announces today, that CEO Mathias Svahn has been invited to speak at the annual BiotechBuilders event held today, 28th of September 2018. Mathias Svahn will also give a presentation at the Nordic Life Science Days, which will be held 10th-12th of September 2018.
The BiotechBuilders event which is held today, 28th of September 2018, has invited CEO Mathias Svahn to speak about NXTCL and how the company has developed over time. The title of his presentation is: “Turning opportunity into productivity, starting a stem cell clinical trial in record speed”. BiotechBuilders is an invitation only networking organization for entrepreneurs and business professional in the life science industry and brings together executives in the Swedish life science sector for a day of networking and team building.
NXTCL will also be present at the Nordic Life Science Days which will be held 10th-12th of September 2018 at the Stockholm Waterfront. During these days NXTCL will be represented by CEO Mathias Svahn and CFO Leo Groenewegen and this event is a great time for growing the company’s network and to engage in interesting activities. On the 11th of September there will be a short company presentation where NXTCL will present its activities, what the company has achieved so far and where the company is heading in the future.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.